Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1.
Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.
Heslop
H E
HE
Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN 38101, USA.
Benaim
E
E
Brenner
M K
MK
Krance
R A
RA
Stricklin
L M
LM
Rochester
R J
RJ
Billing
R
R
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000943:Antigens, Differentiation / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D005544:Forecasting; D006017:Glycolipids / Q000276:immunology*; D006086:Graft vs Host Disease / Q000145:classification / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D016867:Immunocompromised Host; D007075:Immunoglobulin M / Q000627:therapeutic use*; D007223:Infant; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008563:Membrane Lipids / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use*; D012074:Remission Induction; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D006017:Glycolipids; D007075:Immunoglobulin M; D008563:Membrane Lipids; D008775:Methylprednisolone